⌕
Definium Therapeutics · DFTX · Nasdaq
Tenet 50 · Mixed
Compare
$29.38−2.59%At closeTenet 50 · Mixed
$29.38−0.78 (−2.59%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Definium Therapeutics (DFTX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● The Motley FoolNov 16, 2026 · 17:45 ET
Definium Therapeutics: 3 Key Takeaways for Long-Term Investors

Definium Therapeutics held $1.05 billion in cash on Sept. 30, 2026. Management expects cash resources to fund planned operations into 2030.…

● MarketBeatNov 11, 2026 · 05:12 ET
Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Definium Therapeutics NASDAQ: DFTX plans to submit a new drug application to the U.S. Food and Drug Administration for its LSD formulation DT120 in the first half of next year, following positive results from three Phase…

● Seeking AlphaNov 10, 2026 · 13:34 ET
Definium Q3 Earnings: Psychedelics Approval Beckons But Valuation Seems Inflated

Definium Therapeutics, Inc. reported strong Phase 3 results for DT120 in both GAD and MDD, positioning for an NDA filing in H1 2026. DFTX holds over $1bn in cash, supporting operations into 2030, and is preparing for a p…

● Seeking AlphaNov 10, 2026 · 04:01 ET
Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call Transcript

Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call Transcript…

● MarketBeatNov 9, 2026 · 20:15 ET
What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call

Definium Therapeutics NASDAQ: DFTX plans to file a new drug application for its psychiatric treatment candidate DT120 ODT in the first half of 2027, following positive results from three Phase 3 studies in generalized an…

● Business WireNov 9, 2026 · 16:01 ET
Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

NEW YORK--(BUSINESS WIRE)-- #GAD--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address …

● Business WireNov 9, 2026 · 07:01 ETCOMPANY'S OWN WORDS
Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of p…

● Business WireNov 4, 2026 · 07:00 ET
Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress

NEW YORK--(BUSINESS WIRE)-- #ClinicalTrials--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended …

● Business WireNov 3, 2026 · 07:01 ETCOMPANY'S OWN WORDS
Definium Therapeutics to Participate at Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underly…

● Business WireOct 26, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of p…

● Defense WorldOct 22, 2026 · 02:28 ET
Definium Therapeutics, Inc. (NASDAQ:DFTX) Stock Has Average Target Price of $66.00 According to Analysts

Shares of Definium Therapeutics, Inc. (NASDAQ: DFTX - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-one brokerages that are presently covering the company, Marketbeat.com reports. One…

● Business WireOct 13, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of p…

● Business WireSep 28, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of p…

● Defense WorldSep 24, 2026 · 02:03 ET
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression

Definium Therapeutics (NASDAQ: DFTX) Chief Medical Officer Dan Karlin said the company's recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder, or GAD, and major…

● Defense WorldSep 21, 2026 · 02:03 ET
Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study

Definium Therapeutics (NASDAQ: DFTX) reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the single-dose treatment …

● Zacks Investment ResearchSep 15, 2026 · 11:20 ET
Definium Reports Second Phase III Success in Anxiety Disorder Program

DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.…

● Seeking AlphaSep 14, 2026 · 14:31 ET
Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder Transcript

Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder Transcript…

● GuruFocusSep 14, 2026 · 12:14 ET
Definium Therapeutics (DFTX) Achieves Positive Results in Phase 3 Study for DT120 ODT

Definium Therapeutics (DFTX) has seen a significant rise in its stock price following the announcement of positive topline results from its Phase 3 Panorama stu…

● BenzingaSep 14, 2026 · 11:13 ET
Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy'

Definium Therapeutics Inc. (NASDAQ:DFTX) on Monday released topline results from Panorama, its second Phase 3 study evaluating DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disor…

● Business WireSep 14, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underly…

● Business WireSep 14, 2026 · 06:00 ETCOMPANY'S OWN WORDS
Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of p…

● Business WireSep 10, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of p…

● Business WireSep 8, 2026 · 07:00 ET
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of p…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just DFTX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.